Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective | Zendy

Patrick Van Winkle | Zendy; Raoul J. Burchette | Zendy; Raymond Kim | Zendy; Rukmani Raghunathan | Zendy; Naveen Qureshi | Zendy

Open Access

Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective

Author(s) -

Patrick Van Winkle,

Raoul J. Burchette,

Raymond Kim,

Rukmani Raghunathan,

Naveen Qureshi

Publication year - 2018

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/17-141

Subject(s) - medicine , hypogammaglobulinemia , odds ratio , maintenance therapy , confidence interval , fungemia , acute lymphocytic leukemia , retrospective cohort study , chemotherapy , bacteremia , pediatrics , surgery , leukemia , immunology , antibody , lymphoblastic leukemia , antibiotics , mycosis , microbiology and biotechnology , biology

Children with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) experience hypogammaglobulinemia and are at risk of sepsis during maintenance chemotherapy. Intravenous immunoglobulin (IVIG) has been used to try to circumvent this risk, but no data exist regarding its safety and prevalence in a health maintenance organization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research